On Tuesday, June 23, 2026, the biotech ticker that moved was GALT, and the move was violent. Stocktwits flagged the session at 22% and called it, in a headline, “On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial”. Zacks, writing the next morning, put the close at 11.4% and dated the cause precisely: Galectin Therapeutics said it had secured FDA agreement on the main elements of belapectin’s late-stage development program. The drug is a galectin-3 inhibitor, and it is the only candidate the company has in the clinic. For a name that had spent the year going the other way, the session was a statement.
The instrument was bureaucratic, which in this industry is the whole game: an in-person Type C meeting, out of which Galectin won agreement on the phase III study design, the primary endpoint, the central review methodology and the regulatory frame around all of it. The company plans to file the final phase III protocol during the third quarter of 2026 and, alongside it, look for strategic and financial partners to carry the drug toward market. In Zacks’ summary, “The FDA feedback provides greater clarity on the clinical and regulatory pathway toward potential approval”, and that clarity is the asset: a path the agency has effectively pre-approved in outline removes the guesswork that investors price as risk.
The target explains why anyone cares. Belapectin is aimed at MASH cirrhosis with portal hypertension, “a population with limited treatment options and a high risk of progressing to life-threatening liver complications”. The agreed primary endpoint is a composite liver outcome, and its centerpiece is “the prevention of large esophageal varices greater than 5 mm”, a reading Zacks calls “a clinically meaningful marker of worsening portal hypertension and disease progression”. Even the measurement is settled: a blinded central review of the endoscopies, a method “developed and successfully implemented in the company’s global phase IIb/III NAVIGATE study”, carried into the new trial with the agency’s acceptance.
The evidence beneath the plan is a mixed bag, told honestly. NAVIGATE dosed patients intravenously every two weeks for 18 months, at 2 mg or 4 mg per kilogram of lean body mass. In the intent-to-treat population, the lower dose cut the incidence of esophageal varices by 43.2% against placebo, though the composite endpoint “did not achieve statistical significance”. The per-protocol crowd did better, with 49.3% fewer cases, and among American patients in that group the reduction reached 68.1%, alongside a favorable safety profile and biomarker readings pointing to less inflammation and fibrogenesis. Galectin will carry only the 2 mg dose into phase III, on the strength of those signals.
The broader stakes concern what kind of approval is on the table. The FDA put belapectin on the traditional pathway rather than the accelerated route available to earlier-stage MASH populations, and agreed the composite endpoints and study framework can support a full approval application; recent agency guidance that a single adequate, well-controlled confirmatory study may suffice points to a streamlined run. The context tempers the party. The stock entered the week down 25% for the year against a 7.9% industry decline, December 2025 had brought a one-day 30% collapse, dramatic enough that a Stocktwits headline asked “Why Did GALT Shares Plummet Over 30% Today?”, and a law-firm fraud-investigation notice closed out that same month. Zacks itself rates the shares a “Zacks Rank #4 (Sell)”. The calculus, then, is an odd one: a company with one drug, no partner and a Sell rating, holding an FDA-endorsed map to a decisive trial. What the surge signals is that in biotech, regulatory certainty is the scarcest commodity on the board.
Sources
- GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH
- Galectin Therapeutics Inc. Common Stock (GALT) Stock Price: Nov 2 Close $3.33 | Gotrade
